Listen & Learn - EU Joint Clinical Assessment (JCA) & drug access
Do., 15. Mai
|Visio conference - cf link below
Orestis Lazos will talk about the history of the JCA and its aspirations, as well as key aspects relevant to manufacturers, uncertainties and unknowns. We will also discuss what JCA could become.
Time & Location
15. Mai 2025, 12:30 – 13:30
Visio conference - cf link below
Guests
About the event
This session is free of charge. Please confirm your attendance by booking a ticket.
My aspiration for this event is to provide a brief background on the JCA, primarily for people who are adjacent to market access and HTA, in order to understand how access may be evolving at the EU level (and implications for ex-EU) and stimulate a conversation about what it may mean for manufacturers of different sizes, clinical development, and decision-making. I will also provide a snapshot of the narrative’s evolution, and what I believe to be a pragmatic way forward, fostering an open dialogue where attendees can contribute their feedback, ask questions, and challenge my thinking. Broadly, it will benefit attendees looking to stay up to date with regulatory development, understanding potential challenges and unknowns, or open up topics for discussion with peers and colleagues.
This session is brought to HCD by Orestis Lazos - Former…